大面积巴雷特食管癌普遍采用内镜黏膜下剥离术的肿瘤学影响
这项多中心回顾性观察研究比较了ESD优先策略(2017-2024年)与历史选择性ESD策略(2004-2016年)对巴雷特食管癌的肿瘤学效果。结果显示,ESD优先策略使基底R0切除率从69.7%提高到91.2%,T1b病变的治愈性切除率增加且复发率降低,支持对所有较大巴雷特食管癌常规采用ESD。
要点
- 对>15mm的巴雷特食管癌优先采用ESD可提高基底R0切除率。
- T1b病变从ESD优先策略中获益最大,治愈性切除增加、复发减少。
- ESD较EMR获得更高的2年无癌生存率。
核心结论
- 对>15mm的巴雷特食管癌优先采用ESD可改善基底R0切除、减少复发并提高T1b病变的短期生存,支持对所有较大巴雷特食管癌常规采用ESD。
研究设计与样本
- 多中心回顾性观察研究,比较ESD优先策略(2017-2024年)与历史选择性ESD策略(2004-2016年),共纳入542例患者、581次切除,中位病变大小20mm。
主要发现
- 第二期癌症负荷更高(52.3% vs 34.9%),ESD使用率更高(77.1% vs 21.2%)。
- 基底R0切除率从69.7%提高到91.2%(p<0.001),T1b病变从33.3%提高到81.9%(p<0.001)。
- T1b癌症中,治愈性切除率从9.5%提高到30.5%(p=0.043),复发率从55.6%降至23.6%(p=0.043)。
- ESD的2年无癌生存率高于EMR(87.4% vs 50%,p=0.021)。
- 不良事件发生率低(2.2%),两种技术间相似。
关键数值与推荐
- 内镜下可治愈的巴雷特食管癌包括T1a和部分早期T1b病变。
- 两个时期均基于内镜下浸润评估进行病变分配。
临床怎么用
- 对怀疑>15mm的巴雷特食管癌应优先选择ESD而非EMR,以实现整块R0切除。
- T1b病变采用ESD可提高治愈性切除机会并降低复发风险。
局限性
- 回顾性观察设计,可能存在选择偏倚。
- 两个时期间隔较长,其他诊疗因素可能影响结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oncological principles favour en bloc R0 excision for curative endoscopic resection. In Barrett's neoplasia, endoscopically curable cancers include T1a and selected early T1b disease. Although endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are established treatments, optimal lesion selection remains debated. OBJECTIVE: To evaluate the oncological impact of two selective resection strategies: (1) prioritising ESD for suspected Barrett's cancers >15 mm and (2) a historical approach reserving ESD mainly for advanced cancers. DESIGN: Multicentre retrospective observational study comparing an ESD-first strategy (period 2, 2017-2024) with a historical selective ESD approach (period 1, 2004-2016). Lesion allocation was based on endoscopic assessment of invasion in both periods. Outcomes included basal R0 resection, curative resection, recurrence and adverse events. RESULTS: A total of 581 resections were performed in 542 patients (median lesion size 20 mm). Cancer was present in 271 cases (178 T1a and 93 T1b). Period 2 had a higher cancer burden (52.3% vs 34.9%) and greater ESD use (77.1% vs 21.2%). Basal R0 resection improved from 69.7% to 91.2% (p<0.001), with the greatest benefit in T1b lesions (33.3% to 81.9%, p<0.001). In T1b cancers, curative resection increased (9.5% to 30.5%, p=0.043) and recurrence decreased (55.6% to 23.6%, p=0.043). ESD achieved higher 2-year cancer-free survival than EMR (87.4% vs 50%, p=0.021). Adverse events were infrequent (2.2%) and similar between techniques. CONCLUSION: Prioritising ESD for Barrett's cancers >15 mm improves basal R0 resection, reduces recurrence and improves short-term survival for T1b disease, supporting routine ESD for all larger Barrett's cancers.
引用
- Gupta S, Bucalau AM, Mandarino FV, et al. Oncological impact of universal endoscopic submucosal dissection for large Barrett's cancers. Gut. 2026. PMID: 41545198. doi:10.1136/gutjnl-2025-337434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。